Home
Clinical Trials
Partnerships
Contact Us
News & Resources
Careers
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Disease
Oncology
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Publications
Early/Expanded Access Policy
Our Science and Technology
Investors
Press Releases
Events and Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Diseases
Oncology
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Publications
Early/Expanded Access Policy
Our Science and Technology
News and Resources
News
Posters
Publications
Videos
Investors
Press Releases
Company Information
Corporate Governance
Events and Presentations
SEC Filings
Stock Information
Careers
Partnerships
Contact Us
Search our website
Respiratory syncytial virus (“RSV”)
VBI to Present Update and New Data Supporting its RSV and CMV Vaccine Programs at the World Vaccine Congress Europe
November 6th, 2015
RSV Infection in Elderly and High-Risk Adults
September 17th, 2015
RSV Infection in Infants and Young Children
September 10th, 2015
VBI Vaccines Awarded NRC-IRAP Funding to Leverage its eVLP Platform in the Development of a Novel RSV Vaccine Candidate
September 8th, 2015
Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI
Sign Up Now
